CHIROSCIENCE LEVOBUPIVACAINE NDA FILING SET FOR EARLY 1998, SEPRACOR R-ALBUTEROL IN 1997; FDA CONSIDERING "SHIFT IN EXPECTATION" FOR SINGLE ISOMER DEVELOPMENT
Chiroscience anticipates a first quarter 1998 NDA filing for levobupivacaine, a single isomer of bupivacaine, Chiroscience Medical Director Brian Gennery, MD, said Jan. 14 at a conference on stereoisomers sponsored by Georgetown University's Center for Drug Development Science.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth